search
        Home > Projects > Infection and immunity > AmpVacs (Infectious diseases)    
Cancer
Cardiovascular diseases
Neurodegenerative diseases
Infection and immunity
Translational Research IT (TraIT)
 
 
 
AmpVacs
 
Design and use of enhanced T cell antigens and T cell detection technology for human disease 
 
 
Principal Investigator: Roel Melsert, Sanquin
CTMM Program manager: Henny Bruinewoud
 
 - R. Melsert PI AmpVacs project _low res.JPG
Roel Melsert, Sanquin
 
 
Dr. Ron van Eijk, former PI of the AmpVacs project (deceased June 2, 2011):
 
“Starting the AmpVacs project is a first and major step for translational research at a national and international level aiming at the development of a broadly protective synthetic influenza A vaccine. Further development and evaluation of the combined technologies of the contributing parties in the fields of T cell epitope identification, clinical imaging/monitoring, and vaccine formulation will be of significant value for future vaccine design.”
Imagine a broadly protective synthetic influenza A vaccine
 
Influenza A infections remain a substantial health threat, as revealed by the significant annual influenza A-related morbidity and mortality. Both the preparation for an influenza A pandemic and the consequences of such a pandemic when manifested cause substantial socio-economical costs. Protection afforded by traditional influenza A vaccines is mediated in large part by antibodies. In contrast, induction of cytotoxic T cells, the other effector arm of the adaptive immune system is highly inefficient.  Notably, efficient induction of cytotoxic T cell responses would be highly attractive, as contrary to the molecular structures recognized by antibodies, the structures recognized by cytotoxic T cells are in large part conserved between different influenza A subtypes.
Based on this notion and the proven protective effect of cytotoxic T cells on influenza A infection in preclinical models, the AmpVacs consortium will develop an innovative fully synthetic influenza A vaccine component. To achieve this aim, the consortium will build on in-house technologies developed by the partners. Specifically, the consortium will make use of T cell imaging technology developed by one of the partners for the generation of a database of T cell epitopes. This database will then be utilized for the development and evaluation of a fully synthetic influenza A vaccine component, using specific formulation technology of the partners. Thus, the central aim of the consortium is to develop a broadly protective synthetic influenza A vaccine component that in combination with classical antibody-stimulating vaccines will induce protection against future influenza A threats. Notably, the development of the multiplexed T cell imaging technology for the diagnostics of human immune function that this project will achieve will form a major fringe benefit of the project that will be of broad value for future vaccine design.
                                                                                           Full text              
 
Partners in AmpVacs:
 
Netherlands Cancer Institute (NKI)
Intravacc (formerly RIVM)
Sanquin Blood Supply
 
 
AmpVacs project presentation at the CTMM Annual Meeting 2010: PDF (download)
 
 
General
 
The three Public Private Partnerships BMM, CTMM and TI Pharma initiated a call for proposals for research focused on the interface of the three institutes: Imaging Guided and Targeted Drug Delivery.
The projects emerging from this joint call for proposals represent the first example of an interdisciplinary public-private consortium that encompasses competencies from all three institutes. Projects are performed by academia and industry in close cooperation.
AmpVacs is one of the joint call projects funded by CTMM.
 
 
 
26 November 2010, revised 15 May 2013 
 
 
   
   
   


 
   

 

 

© CTMM, Center for Translational Molecular Medicine | Contact | Login | Disclaimer